Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

SAB Biotherapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 3 Sessa Capital (Master), L.P. (Director) has filed a Form 3 on SAB Biotherapeutics, Inc.
10/10/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
10/02/2023 8-K Quarterly results
08/21/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/21/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
08/21/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
07/31/2023 8-K Quarterly results
07/31/2023 AW Form AW - Amendment Withdrawal Request:
07/10/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
07/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/18/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation "
05/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/01/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/28/2023 10-K/A Annual Report for the period ended December 31, 2021 [amend]
04/28/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Press Release of the Company"
04/19/2023 8-K Quarterly results
04/14/2023 10-K Annual Report for the period ended December 31, 2022
04/14/2023 8-K Quarterly results
04/05/2023 4 Lucera Erick (Director) has filed a Form 4 on SAB Biotherapeutics, Inc.
Txns: Granted 25,000 options to buy @ $0.465, valued at $11.6k
04/05/2023 3 Lucera Erick (Director) has filed a Form 3 on SAB Biotherapeutics, Inc.
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors SIOUX FALLS, S.D., April 4, 2023 -- SAB Biotherapeutics , , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB’s Board of Directors, effective April 4, 2023. Most recently, Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused biopharmaceutical company, from January 202..."
03/31/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/31/2023 8-K Quarterly results
Docs: "Press Release of the Company"
03/24/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
03/16/2023 4 Kropotova Alexandra (Chief Medical Officer) has filed a Form 4 on SAB Biotherapeutics, Inc.
Txns: Granted 275,000 shares @ $0
03/16/2023 4 Sullivan Eddie Joe (CEO) has filed a Form 4 on SAB Biotherapeutics, Inc.
Txns: Granted 525,000 options to buy @ $0.54, valued at $283.5k
03/16/2023 4 Reich Samuel J (Executive Chairman) has filed a Form 4 on SAB Biotherapeutics, Inc.
Txns: Granted 525,000 options to buy @ $0.54, valued at $283.5k
03/16/2023 4 Bausch Christoph Lawrence (COO) has filed a Form 4 on SAB Biotherapeutics, Inc.
Txns: Granted 275,000 options to buy @ $0.54, valued at $148.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy